恒瑞医药：获得四项药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trial notifications for four drugs, indicating progress in its drug development pipeline [1] Drug Development Summary - SHR-8068 Injection: A fully human anti-CTLA-4 monoclonal antibody with a development investment of approximately 214 million yuan [1] - Abediterol Injection: A self-developed humanized anti-PD-L1 monoclonal antibody with a development investment of approximately 887 million yuan [1] - Bevacizumab Injection: A humanized anti-VEGF monoclonal antibody with a development investment of approximately 345 million yuan [1] - Apatinib Mesylate Tablets: An innovative small molecule targeted drug with a development investment of approximately 587 million yuan [1] Regulatory Process Summary - Following the approval of the clinical trial notifications, the drugs must undergo clinical trials and receive further review and approval from the National Medical Products Administration before they can be manufactured and marketed [1]